UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2020
Commission File Number 001-15170
GlaxoSmithKline plc
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc
GSK publishes provisional dividend dates
GSK announces the following dividend dates for 2021:
Results | Announcement date | Ex-dividend date | Record date | Last date for DRIP elections | Payable |
Q1 2021 | Wednesday 28 April 2021 | Thursday 20 May 2021 | Friday 21 May 2021 | Thursday 17 June 2021 | Thursday 8 July 2021 |
Q2 2021 | Wednesday 28 July 2021 | Thursday 19 August 2021 | Friday 20 August 2021 | Thursday 16 September 2021 | Thursday 7 October 2021 |
Q3 2021 | Wednesday 27 October 2021 | Thursday 18 November 2021 | Friday 19 November 2021 | Monday 20 December 2021 | Thursday 13 January 2022 |
Q4 2021 (Final) | Wednesday 9 February 2022 | Thursday 24 February 2022 | Friday 25 February 2022 | Thursday 17 March 2022 | Thursday 7 April 2022 |
These dates are indicative and may be subject to change.
V A Whyte
Company Secretary
27 November 2020
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc | |
(Registrant) | |
Date: November 27, 2020 | |
By:/s/ VICTORIA WHYTE -------------------------- | |
Victoria Whyte | |
Authorised Signatory for and on | |
behalf of GlaxoSmithKline plc |